Core Viewpoint - WuXi AppTec plans to sell assets to Hillhouse Capital for 2.8 billion yuan, which is expected to significantly boost the company's net profit in 2025 [2][20]. Group 1: Transaction Details - WuXi AppTec's wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., intends to transfer 100% equity of Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jishi Pharmaceutical Technology Co., Ltd. to companies established by Hillhouse Capital [9][12]. - The transaction is based on a benchmark equity transfer price of 2.8 billion yuan, with the final price to be determined by the financial conditions of the transferred companies and their performance from 2026 to 2028 [13][21]. Group 2: Financial Performance - For the first three quarters of 2025, WuXi AppTec reported a year-on-year increase in net profit attributable to shareholders of 84.84%, reaching 12.076 billion yuan, driven by a focus on the CRDMO business model and gains from the sale of shares in WuXi XDC Cayman Inc. [5][24]. - The net profit of Kande Hongyi for 2024 and the first three quarters of 2025 was -42.47 million yuan and -75.45 million yuan, respectively, while Jishi Pharmaceutical reported net profits of 313.13 million yuan and 162.79 million yuan for the same periods [15][19]. Group 3: Strategic Focus - The company aims to enhance its focus on the CRDMO business model, which includes drug discovery, laboratory testing, and process development and production services, to accelerate global capabilities and capacity deployment [24].

Core Insights - WuXi AppTec (02359) reported a revenue of RMB 32.86 billion for the first three quarters of 2025, representing a year-on-year growth of 18.6% [1] - The revenue from continuing operations increased by 22.5% year-on-year [1] - The net profit attributable to shareholders reached RMB 12.076 billion, showing a significant year-on-year increase of 84.84% [1] - Basic earnings per share stood at RMB 4.25 [1] Revenue Projections - The company expects revenue from continuing operations to return to double-digit growth, with the growth rate revised from 13-17% to 17-18% [1] - The overall revenue forecast for the year has been adjusted from RMB 42.5-43.5 billion to RMB 43.5-44 billion [1] Business Focus - The company will concentrate on its CRDMO core business and aims to continuously improve operational efficiency [1]

格隆汇10月26日丨药明康德(02359.HK)公告，公司2025年前三季度实现营业收入328.57亿元，同比增长 18.61%；归属于上市公司股东的净利润120.76亿元，同比增幅84.84%。基本每股收益4.25元。 公司持续聚焦及加强CRDMO业务模式，营业收入持续增长，同时持续优化生产工艺和经营效率，以及 临床后期和商业化大项目增长带来的产能效率不断提升，提高了整体的盈利能力；同时，公司出售持有 的联营企业WuXi XDC CaymanInc.部分股票的收益，进一步提升了公司的利润。 ...

Core Viewpoint - WuXi AppTec reported significant growth in revenue and net profit for the first three quarters of 2025, driven by its focus on the CRDMO business model and operational efficiency improvements [1][3]. Financial Performance - For the first three quarters of 2025, WuXi AppTec achieved operating revenue of RMB 32.857 billion, a year-on-year increase of 18.61% [1]. - The net profit attributable to shareholders reached RMB 12.076 billion, reflecting a substantial year-on-year growth of 84.84% [1][2]. - As of September 30, 2025, the company had a backlog of orders amounting to RMB 59.88 billion, up 41.2% year-on-year [2]. Revenue Breakdown - Revenue from continuous operations for the first three quarters was RMB 32.45 billion, with contributions from various regions: - Revenue from U.S. clients: RMB 22.15 billion, up 31.9% - Revenue from European clients: RMB 3.84 billion, up 13.5% - Revenue from Chinese clients: RMB 5.04 billion, up 0.5% - Revenue from other regions: RMB 1.42 billion, up 9.2% [2]. - The chemical business generated RMB 25.98 billion, a growth of 29.3% [2]. Strategic Moves - WuXi AppTec announced the sale of 100% equity in two subsidiaries for a base price of RMB 2.8 billion to a company under Hillhouse Capital [4]. - The divestiture aligns with the company's strategy to focus on its core CRDMO business, enhancing its global capabilities and operational capacity [4][5]. Future Outlook - The company expects continuous operations revenue growth to return to double digits, with an adjusted growth rate forecast of 17-18% [3]. - Overall revenue guidance for the year has been raised to between RMB 43.5 billion and RMB 44 billion [3].

药明康德表示，本次出售康德弘翼及津石医药100%股权，是公司基于聚焦CRDMO业务模式，专注药物 发现、实验室测试及工艺开发和生产服务考虑所实施，可为公司加速全球化能力和产能的投放提供资金 支持，符合公司发展战略和长远利益。 北京商报讯（记者 丁宁）10月26日晚间，药明康德（603259）发布公告称，公司全资子公司上海药明 康德新药开发有限公司拟以28亿元（为基准股权转让价款，最终股权转让价款将基于交易协议的相关约 定进行调整）的对价向上海世和融企业管理咨询有限公司及上海世和慕企业管理咨询有限公司转让其所 持有的上海康德弘翼医学临床研究有限公司（以下简称"康德弘翼"）和上海药明津石医药科技有限公司 （以下简称"津石医药"）100%股权。 ...

Core Viewpoint - WuXi AppTec (603259.SH) announced the sale of 100% equity in two subsidiaries, Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., for a base price of RMB 2.8 billion, aiming to focus on its CRDMO business model and enhance global capabilities and capacity [1][2]. Group 1 - The transaction involves the complete transfer of equity in both target companies as an indivisible part of a comprehensive deal [1]. - The sale aligns with the company's strategy to concentrate on drug discovery, laboratory testing, and process development and production services [2]. - The target companies generated approximately RMB 1.16 billion in revenue from January to September 2025, accounting for about 3.5% of the company's total revenue for the same period [2]. Group 2 - The net profit of the target companies for the same period was approximately RMB 90 million, representing about 0.7% of the company's net profit [2]. - The transaction is expected to provide financial support for the company's accelerated global capacity deployment [2].

药明康德10月26日公告，2025年第三季度实现营业收入120.57亿元，同比增长15.26%；归属于上市公司 股东的净利润35.15亿元，同比增长53.27%；基本每股收益1.24元。 前三季度实现营业收入328.57亿 元，同比增长18.61%；归属于上市公司股东的净利润120.76亿元，同比增长84.84%；基本每股收益4.25 元。 ...

Core Viewpoint - Zhaoyan New Drug (06127) has seen a stock price increase of over 3%, currently trading at 19.87 HKD, following the FDA's approval of YK012 for clinical trials, marking a significant milestone in the development of innovative therapies for primary membranous nephropathy (pMN) [1] Group 1: Company Developments - YK012, a bispecific antibody targeting CD19/CD3, has received IND approval from the FDA for treating pMN, making it the first T cell engager (TCE) bispecific antibody approved for this indication globally [1] - Zhaoyan New Drug is a non-clinical CRO partner for YK012, participating in pharmacokinetic services and toxicology testing during the non-clinical trial phase [1] Group 2: Research and Development Strategy - The development of YK012 is supported by a dual-center strategy with a headquarters in Beijing and a wholly-owned subsidiary, Excyte LLC, in the United States [1] - Following the FDA IND approval, the company plans to initiate international multi-center clinical studies, complementing ongoing multi-center trials in China led by Professor Zhao Minghui from Peking University First Hospital, to accelerate global research progress [1]

Macro Dynamics - The People's Bank of China will conduct a 600 billion yuan reverse repurchase operation on October 15, 2025, with a term of 6 months [2] Industry Developments - Shanghai's Economic and Information Commission has issued an action plan for the high-quality development of the smart terminal industry (2026-2027), focusing on the layout of core chips such as SoC and CPU, covering X86, ARM, and RISC-V technology routes [3] - The World Steel Association forecasts that global steel demand will reach approximately 1.75 billion tons in 2025, remaining stable compared to 2024, with a mild rebound of 1.3% expected in 2026 [5] Company News - Goldman Sachs has upgraded the rating of Tigermed's A-shares from "Neutral" to "Buy," raising the target price from 62.1 yuan to 77.1 yuan, citing attractive entry points and expected growth in new orders [7] - DJI has filed an appeal against the U.S. Department of Defense regarding its designation as a "Chinese military enterprise," asserting its commitment to preventing the misuse of its products for military purposes [13] - JD.com announced a collaboration with CATL and GAC Group to launch a new car on November 9, clarifying that JD will not be directly involved in manufacturing [14] - G-bits expects a net profit increase of 57% to 86% year-on-year for the first three quarters of 2025, driven by new game launches [15] - Grand Materials announced that its chairman has been placed under detention, but the company's operations remain normal [16] - Shenghe Resources anticipates a net profit increase of 696.82% to 782.96% for the first three quarters of 2025, attributed to favorable market conditions for rare earth products [18] - Shandong Gold expects a net profit increase of 83.9% to 98.5% for the first three quarters of 2025, driven by improved operational efficiency and rising gold prices [19] - Longbai Group has filed a lawsuit for 1.3105 billion yuan due to the infringement of trade secrets [20]

Core Viewpoint - Sunshine Nuohua's stock price has declined for five consecutive days, with a total drop of 11.3% during this period, indicating potential concerns among investors regarding the company's performance and market conditions [1]. Company Overview - Sunshine Nuohua Pharmaceutical Research Co., Ltd. is located in Changping District, Beijing, and was established on March 9, 2009. The company went public on June 21, 2021. Its main business involves the development of generic drugs, consistency evaluation, and innovative drug development, primarily focusing on pharmaceutical research, clinical trials, and bioanalysis [1]. - The revenue composition of the company is heavily weighted towards CRO (Contract Research Organization) services, accounting for 99.91% of total revenue, with other services contributing only 0.09% [1]. Shareholder Insights - Anxin Fund's Anxin Medical Health Stock A (010709) is among the top ten circulating shareholders of Sunshine Nuohua. In the second quarter, it reduced its holdings by 266,500 shares, retaining 1.442 million shares, which represents 1.29% of the circulating shares. The estimated floating loss today is approximately 1.5285 million yuan, with a total floating loss of 10.8872 million yuan over the five-day decline [2]. - Anxin Medical Health Stock A was established on January 12, 2021, with a current scale of 442 million yuan. Year-to-date returns stand at 63.14%, ranking 222 out of 4220 in its category, while the one-year return is 53.22%, ranking 797 out of 3857 [2]. Fund Positioning - Anxin Medical Health Stock A has Sunshine Nuohua as its fourth-largest holding, with 1.442 million shares representing 7.61% of the fund's net value. The estimated floating loss for today is around 1.5285 million yuan, with a cumulative floating loss of 10.8872 million yuan during the recent five-day decline [3].